Cell Therapeutics, Inc. (NASDAQ:CTIC)

CAPS Rating: 2 out of 5

The Company develops, acquires and commercializes novel treatments for cancer and focuses its research and in-licensing activities on identifying and developing new, less toxic and effective ways to treat cancer.

Recs

0
Player Avatar liken22 (< 20) Submitted: 1/30/2012 10:59:47 AM : Outperform Start Price: $1.08 CTIC Score: -16.86

Hit the lowest cap in a long time, so I think will go up

Featured Broker Partners


Advertisement